[When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis].
Farnier
M
M
Point Médical, Rond Point de la Nation, 21000 Dijon.
Bonnet
F
F
Bruckert
E
E
Ferrières
J
J
Paillard
F
F
D000924:Anticholesteremic Agents / Q000008:administration & dosage; D050197:Atherosclerosis / Q000188:drug therapy*; D001384:Azetidines / Q000008:administration & dosage; D002792:Cholestyramine Resin / Q000008:administration & dosage; D002995:Clofibric Acid / Q000008:administration & dosage; D000075202:Contraindications; D004338:Drug Combinations; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D009525:Niacin / Q000008:administration & dosage; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002792:Cholestyramine Resin; D009525:Niacin; D002995:Clofibric Acid; D000069438:Ezetimibe